Oncocyte Corp., a diagnostics technology company based in Irvine, California, announced on May 19, 2025, that its next-generation lab-developed test (LDT) called GraftAssureCore has received a favorable pricing update. Trading on Nasdaq under OCX, the company's new reimbursement rate for the test enhances its competitiveness in the transplant rejection testing sector. This development indicates a promising outlook for Oncocyte Corp. as it operates within an estimated total addressable market of $1 billion.